{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:03:32Z","timestamp":1784919812949,"version":"3.55.0"},"reference-count":149,"publisher":"Japanese Society of Internal Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,1,15]]},"DOI":"10.2169\/internalmedicine.5318-25","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T18:08:25Z","timestamp":1747850905000},"page":"203-213","source":"Crossref","is-referenced-by-count":5,"title":["Gut Microbiota and Interorgan Communication Among the Gut, Brain, and Beyond"],"prefix":"10.2169","volume":"65","author":[{"given":"Arina","family":"Shigehara","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kiyohara","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Teratani","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Nakamoto","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Mikami","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Kanai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Japan"},{"name":"AMED-CREST, Japan Agency for Medical Research and Development, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Saraiva-Santos T, Zaninelli TH, Pinho-Ribeiro FA. Modulation of host immunity by sensory neurons. Trends Immunol 45: 381-396, 2024.","DOI":"10.1016\/j.it.2024.03.005"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Huh JR, Veiga-Fernandes H. Neuroimmune circuits in inter-organ communication. Nat Rev Immunol 20: 217-228, 2020.","DOI":"10.1038\/s41577-019-0247-z"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Chavan SS, Pavlov VA, Tracey KJ. Mechanisms and therapeutic relevance of neuro-immune communication. Immunity 46: 927-942, 2017.","DOI":"10.1016\/j.immuni.2017.06.008"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Matsubara Y, Kiyohara H, Teratani T, Mikami Y, Kanai T. Organ and brain crosstalk: the liver-brain axis in gastrointestinal, liver, and pancreatic diseases. Neuropharmacology 205: 108915, 2022.","DOI":"10.1016\/j.neuropharm.2021.108915"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kaelberer MM, Buchanan KL, Klein ME, et al. A gut-brain neural circuit for nutrient sensory transduction. Science 361: eaat5236, 2018.","DOI":"10.1126\/science.aat5236"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Muller PA, Schneeberger M, Matheis F, et al. Microbiota modulate sympathetic neurons via a gut-brain circuit. Nature 583: 441-446, 2020.","DOI":"10.1038\/s41586-020-2474-7"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Han W, Tellez LA, Perkins MH, et al. A neural circuit for gut-induced reward. Cell 175: 665-678.e23, 2018.","DOI":"10.1016\/j.cell.2018.08.049"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Carloni S, Bertocchi A, Mancinelli S, et al. Identification of a choroid plexus vascular barrier closing during intestinal inflammation. Science 374: 439-448, 2021.","DOI":"10.1126\/science.abc6108"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Godinho-Silva C, Cardoso F, Veiga-Fernandes H. Neuro-immune cell units: a new paradigm in physiology. Annu Rev Immunol 37: 19-46, 2019.","DOI":"10.1146\/annurev-immunol-042718-041812"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yan M, Man S, Sun B, et al. Gut liver brain axis in diseases: the implications for therapeutic interventions. Signal Transduct Target Ther 8: 443, 2023.","DOI":"10.1038\/s41392-023-01673-4"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Browning KN, Travagli RA. Central control of gastrointestinal motility. Curr Opin Endocrinol Diabetes Obes 26: 11-16, 2019.","DOI":"10.1097\/MED.0000000000000449"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Zhu B, Wang X, Li L. Human gut microbiome: the second genome of human body. Protein Cell 1: 718-725, 2010.","DOI":"10.1007\/s13238-010-0093-z"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Mariat D, Firmesse O, Levenez F, et al. The <i>Firmicutes\/Bacteroidetes<\/i> ratio of the human microbiota changes with age. BMC Microbiol 9: 123, 2009.","DOI":"10.1186\/1471-2180-9-123"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Burrows K, Ngai L, Chiaranunt P, et al. A gut commensal protozoan determines respiratory disease outcomes by shaping pulmonary immunity. Cell 188: 316-330.e12, 2025.","DOI":"10.1016\/j.cell.2024.11.020"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Jordan CKI, Clarke TB. How does the microbiota control systemic innate immunity? Trends Immunol 45: 94-102, 2024.","DOI":"10.1016\/j.it.2023.12.002"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Schroeder BO, B\u00e4ckhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med 22: 1079-1089, 2016.","DOI":"10.1038\/nm.4185"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic T<sub>reg<\/sub> cell homeostasis. Science 341: 569-573, 2013.","DOI":"10.1126\/science.1241165"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461: 1282-1286, 2009.","DOI":"10.1038\/nature08530"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504: 446-450, 2013.","DOI":"10.1038\/nature12721"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Fukuda S, Toh H, Hase K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469: 543-547, 2011.","DOI":"10.1038\/nature09646"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous <i>Clostridium<\/i> species. Science 331: 337-341, 2011.","DOI":"10.1126\/science.1198469"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ramanan D, Pratama A, Zhu Y, et al. Regulatory T cells in the face of the intestinal microbiota. Nat Rev Immunol 23: 749-762, 2023.","DOI":"10.1038\/s41577-023-00890-w"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Haghikia A, J\u00f6rg S, Duscha A, et al. Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine. Immunity 43: 817-829, 2015.","DOI":"10.1016\/j.immuni.2015.09.007"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Atarashi K, Tanoue T, Ando M, et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. Cell 163: 367-380, 2015.","DOI":"10.1016\/j.cell.2015.08.058"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kitamoto S, Nagao-Kitamoto H, Jiao Y, et al. The intermucosal connection between the mouth and gut in commensal pathobiont-driven colitis. Cell 182: 447-462.e14, 2020.","DOI":"10.1016\/j.cell.2020.05.048"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Kobayashi T, Okamoto S, Hisamatsu T, et al. IL23 differentially regulates the Th1\/Th17 balance in ulcerative colitis and Crohn&apos;s disease. Gut 57: 1682-1689, 2008.","DOI":"10.1136\/gut.2007.135053"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Mikami Y, Philips RL, Sciume G, et al. MicroRNA-221 and -222 modulate intestinal inflammatory Th17 cell response as negative feedback regulators downstream of interleukin-23. Immunity 54: 514-525 e6, 2021.","DOI":"10.1016\/j.immuni.2021.02.015"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Mikami Y, Kanai T, Sujino T, et al. Competition between colitogenic Th1 and Th17 cells contributes to the amelioration of colitis. Eur J Immunol 40: 2409-2422, 2010.","DOI":"10.1002\/eji.201040379"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Esplugues E, Huber S, Gagliani N, et al. Control of T<sub>H<\/sub>17 cells occurs in the small intestine. Nature 475: 514-518, 2011.","DOI":"10.1038\/nature10228"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Sano T, Huang W, Hall JA, et al. An IL-23R\/IL-22 circuit regulates epithelial serum amyloid A to promote local effector Th17 responses. Cell 163: 381-393, 2015.","DOI":"10.1016\/j.cell.2015.08.061"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Mao K, Baptista AP, Tamoutounour S, et al. Innate and adaptive lymphocytes sequentially shape the gut microbiota and lipid metabolism. Nature 554: 255-259, 2018.","DOI":"10.1038\/nature25437"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Lee YK, Turner H, Maynard CL, et al. Late developmental plasticity in the T helper 17 lineage. Immunity 30: 92-107, 2009.","DOI":"10.1016\/j.immuni.2008.11.005"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn&apos;s disease. N Engl J Med 367: 1519-1528, 2012.","DOI":"10.1056\/NEJMoa1203572"},{"key":"34","unstructured":"34. Ferrante M, D&apos;Haens G, Jairath V, et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn&apos;s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. Lancet 404: 2423-2436, 2024."},{"key":"35","unstructured":"35. Rubin DT, Allegretti JR, Panes J, et al. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. Lancet 405: 33-49, 2025."},{"key":"36","doi-asserted-by":"publisher","unstructured":"36. Louis E, Schreiber S, Panaccione R, et al. Risankizumab for ulcerative colitis: two randomized clinical trials. JAMA 332: 881-897, 2024.","DOI":"10.1001\/jama.2024.12414"},{"key":"37","doi-asserted-by":"publisher","unstructured":"37. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn&apos;s disease: the ACCENT I randomised trial. Lancet 359: 1541-1549, 2002.","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Brown RL, Sequeira RP, Clarke TB. The microbiota protects against respiratory infection via GM-CSF signaling. Nat Commun 8: 1512, 2017.","DOI":"10.1038\/s41467-017-01803-x"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Deshmukh HS, Liu Y, Menkiti OR, et al. The microbiota regulates neutrophil homeostasis and host resistance to <i>Escherichia coli<\/i> K1 sepsis in neonatal mice. Nat Med 20: 524-530, 2014.","DOI":"10.1038\/nm.3542"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Jordan CKI, Brown RL, Larkinson MLY, Sequeira RP, Edwards AM, Clarke TB. Symbiotic Firmicutes establish mutualism with the host via innate tolerance and resistance to control systemic immunity. Cell Host Microbe 31: 1433-1449.e9, 2023.","DOI":"10.1016\/j.chom.2023.07.008"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Morton AM, Sefik E, Upadhyay R, Weissleder R, Benoist C, Mathis D. Endoscopic photoconversion reveals unexpectedly broad leukocyte trafficking to and from the gut. Proc Natl Acad Sci U S A 111: 6696-6701, 2014.","DOI":"10.1073\/pnas.1405634111"},{"key":"42","doi-asserted-by":"publisher","unstructured":"42. Atarashi K, Tanoue T, Oshima K, et al. T<sub>reg<\/sub> induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500: 232-236, 2013.","DOI":"10.1038\/nature12331"},{"key":"43","doi-asserted-by":"publisher","unstructured":"43. Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology 43: S54-S62, 2006.","DOI":"10.1002\/hep.21060"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Tripathi A, Debelius J, Brenner DA, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 15: 397-411, 2018.","DOI":"10.1038\/s41575-018-0011-z"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Kim YS, Hurley EH, Park Y, Ko S. Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut-liver axis. Exp Mol Med 55: 1380-1387, 2023.","DOI":"10.1038\/s12276-023-01042-9"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. J Hepatol 67: 1298-1323, 2017.","DOI":"10.1016\/j.jhep.2017.07.022"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Horsley-Silva JL, Carey EJ, Lindor KD. Advances in primary sclerosing cholangitis. Lancet Gastroenterol Hepatol 1: 68-77, 2016.","DOI":"10.1016\/S2468-1253(16)30010-3"},{"key":"48","doi-asserted-by":"publisher","unstructured":"48. Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M. Primary sclerosing cholangitis. Lancet 391: 2547-2559, 2018.","DOI":"10.1016\/S0140-6736(18)30300-3"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Mikami Y, Mizuno S, Nakamoto N, et al. Macrophages and dendritic cells emerge in the liver during intestinal inflammation and predispose the liver to inflammation. PLoS One 9: e84619, 2014.","DOI":"10.1371\/journal.pone.0084619"},{"key":"50","doi-asserted-by":"publisher","unstructured":"50. Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482: 179-185, 2012.","DOI":"10.1038\/nature10809"},{"key":"51","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/gutjnl-2015-310500","volume":"66","author":"M Kummen","year":"2017","unstructured":"51. Kummen M, Holm K, Anmarkrud JA, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut 66: 611-619, 2017.","journal-title":"Gut","ISSN":"https:\/\/id.crossref.org\/issn\/0017-5749","issn-type":"print"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Nakamoto N, Sasaki N, Aoki R, et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol 4: 492-503, 2019.","DOI":"10.1038\/s41564-018-0333-1"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Ichikawa M, Nakamoto N, Kredo-Russo S, et al. Bacteriophage therapy against pathological <i>Klebsiella pneumoniae<\/i> ameliorates the course of primary sclerosing cholangitis. Nat Commun 14: 3261, 2023.","DOI":"10.1038\/s41467-023-39029-9"},{"key":"54","doi-asserted-by":"publisher","unstructured":"54. Teratani T, Mikami Y, Nakamoto N, et al. The liver-brain-gut neural arc maintains the T<sub>reg<\/sub> cell niche in the gut. Nature 585: 591-596, 2020.","DOI":"10.1038\/s41586-020-2425-3"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Spengler EK, Loomba R. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mayo Clin Proc 90: 1233-1246, 2015.","DOI":"10.1016\/j.mayocp.2015.06.013"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Kapil S, Duseja A, Sharma BK, et al. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 31: 213-221, 2016.","DOI":"10.1111\/jgh.13058"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Loomba R, Seguritan V, Li W, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab 25: 1054-1062.e5, 2017.","DOI":"10.1016\/j.cmet.2017.04.001"},{"key":"58","doi-asserted-by":"publisher","unstructured":"58. Brandi G, De Lorenzo S, Candela M, et al. Microbiota, NASH, HCC and the potential role of probiotics. Carcinogenesis 38: 231-240, 2017.","DOI":"10.1093\/carcin\/bgx007"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol 13: 412-425, 2016.","DOI":"10.1038\/nrgastro.2016.85"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Brescia P, Rescigno M. The gut vascular barrier: a new player in the gut-liver-brain axis. Trends Mol Med 27: 844-855, 2021.","DOI":"10.1016\/j.molmed.2021.06.007"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Yamagishi R, Kamachi F, Nakamura M, et al. Gasdermin D-mediated release of IL-33 from senescent hepatic stellate cells promotes obesity-associated hepatocellular carcinoma. Sci Immunol 7: eabl7209, 2022.","DOI":"10.1126\/sciimmunol.abl7209"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Varanasi SK, Chen D, Liu Y, et al. Bile acid synthesis impedes tumor-specific T cell responses during liver cancer. Science 387: 192-201, 2025.","DOI":"10.1126\/science.adl4100"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Elamin EE, Masclee AA, Dekker J, Jonkers DM. Ethanol metabolism and its effects on the intestinal epithelial barrier. Nutr Rev 71: 483-499, 2013.","DOI":"10.1111\/nure.12027"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Meijnikman AS, Davids M, Herrema H, et al. Microbiome-derived ethanol in nonalcoholic fatty liver disease. Nat Med 28: 2100-2106, 2022.","DOI":"10.1038\/s41591-022-02016-6"},{"key":"65","doi-asserted-by":"publisher","unstructured":"65. Yan AW, Fouts DE, Brandl J, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 53: 96-105, 2011.","DOI":"10.1002\/hep.24018"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Axelson M, M\u00f6rk B, Sj\u00f6vall J. Ethanol has an acute effect on bile acid biosynthesis in man. FEBS Lett 281: 155-159, 1991.","DOI":"10.1016\/0014-5793(91)80382-D"},{"key":"67","doi-asserted-by":"publisher","unstructured":"67. Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology 148: 30-36, 2015.","DOI":"10.1053\/j.gastro.2014.10.042"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Cella M, Fuchs A, Vermi W, et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 457: 722-725, 2009.","DOI":"10.1038\/nature07537"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Mizuno S, Mikami Y, Kamada N, et al. Cross-talk between ROR\u03b3t<sup>+<\/sup>innate lymphoid cells and intestinal macrophages induces mucosal IL-22 production in Crohn&apos;s disease. Inflamm Bowel Dis 20: 1426-1434, 2014.","DOI":"10.1097\/MIB.0000000000000105"},{"key":"70","doi-asserted-by":"publisher","unstructured":"70. Basu R, O&apos;Quinn DB, Silberger DJ, et al. Th22 cells are an important source of IL-22 for host protection against enteropathogenic bacteria. Immunity 37: 1061-1075, 2012.","DOI":"10.1016\/j.immuni.2012.08.024"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Stevens S, Flavell RA. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 29: 947-957, 2008.","DOI":"10.1016\/j.immuni.2008.11.003"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Sawa S, Lochner M, Satoh-Takayama N, et al. ROR\u03b3t<sup>+<\/sup> innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota. Nat Immunol 12: 320-326, 2011.","DOI":"10.1038\/ni.2002"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Sugimoto K, Ogawa A, Mizoguchi E, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 118: 534-544, 2008.","DOI":"10.1172\/JCI33194"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Shin JH, Seeley RJ. Reg3 proteins as gut hormones? Endocrinology 160: 1506-1514, 2019.","DOI":"10.1210\/en.2019-00073"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Wang L, Fouts DE, St\u00e4rkel P, et al. Intestinal REG3 lectins protect against alcoholic steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation. Cell Host Microbe 19: 227-239, 2016.","DOI":"10.1016\/j.chom.2016.01.003"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Yuan J, Chen C, Cui J, et al. Fatty liver disease caused by high-alcohol-producing <i>Klebsiella pneumoniae<\/i>. Cell Metab 30: 675-688.e7, 2019.","DOI":"10.1016\/j.cmet.2019.08.018"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Tandon P, Berzigotti A. Management of lifestyle factors in individuals with cirrhosis: a pragmatic review. Semin Liver Dis 40: 20-28, 2020.","DOI":"10.1055\/s-0039-1696639"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Sorribas M, Jakob MO, Yilmaz B, et al. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis. J Hepatol 71: 1126-1140, 2019.","DOI":"10.1016\/j.jhep.2019.06.017"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Mouries J, Brescia P, Silvestri A, et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol 71: 1216-1228, 2019.","DOI":"10.1016\/j.jhep.2019.08.005"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Woodhouse CA, Patel VC, Singanayagam A, Shawcross DL. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther 47: 192-202, 2018.","DOI":"10.1111\/apt.14397"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Boicean A, Birlutiu V, Ichim C, Brusnic O, Oni\u015for DM. Fecal microbiota transplantation in liver cirrhosis. Biomedicines 11: 2930, 2023.","DOI":"10.3390\/biomedicines11112930"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Chen Y, Ji F, Guo J, Shi D, Fang D, Li L. Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology. Sci Rep 6: 34055, 2016.","DOI":"10.1038\/srep34055"},{"key":"83","doi-asserted-by":"publisher","unstructured":"83. Camilleri M. Peripheral mechanisms in appetite regulation. Gastroenterology 148: 1219-1233, 2015.","DOI":"10.1053\/j.gastro.2014.09.016"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Gr\u0105t M, Ho\u0142\u00f3wko W, Wronka KM, et al. The relevance of intestinal dysbiosis in liver transplant candidates. Transpl Infect Dis 17: 174-184, 2015.","DOI":"10.1111\/tid.12352"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. Curr Opin Gastroenterol 30: 332-338, 2014.","DOI":"10.1097\/MOG.0000000000000057"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Afecto E, Ponte A, Fernandes S, et al. Fecal microbiota transplantation in hepatic encephalopath: a review of the current evidence and future perspectives. Acta Gastroenterol Belg 84: 87-90, 2021.","DOI":"10.51821\/84.1.884"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Madsen M, Kimer N, Bendtsen F, Petersen AM. Fecal microbiota transplantation in hepatic encephalopathy: a systematic review. Scand J Gastroenterol 56: 560-569, 2021.","DOI":"10.1080\/00365521.2021.1899277"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. Babygirija R, Zheng J, Ludwig K, Takahashi T. Central oxytocin is involved in restoring impaired gastric motility following chronic repeated stress in mice. Am J Physiol Regul Integr Comp Physiol 298: R157-R165, 2010.","DOI":"10.1152\/ajpregu.00328.2009"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Gabanyi I, Lepousez G, Wheeler R, et al. Bacterial sensing via neuronal Nod2 regulates appetite and body temperature. Science 376: eabj3986, 2022.","DOI":"10.1126\/science.abj3986"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Morais LH, Schreiber HL 4th, Mazmanian SK. The gut microbiota-brain axis in behaviour and brain disorders. Nat Rev Microbiol 19: 241-255, 2021.","DOI":"10.1038\/s41579-020-00460-0"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Strandwitz P. Neurotransmitter modulation by the gut microbiota. Brain Res 1693: 128-133, 2018.","DOI":"10.1016\/j.brainres.2018.03.015"},{"key":"92","doi-asserted-by":"publisher","unstructured":"92. Xiang J, Tang J, Kang F, et al. Gut-induced alpha-Synuclein and Tau propagation initiate Parkinson&apos;s and Alzheimer&apos;s disease co-pathology and behavior impairments. Neuron 112: 3585-3601.e5, 2024.","DOI":"10.1016\/j.neuron.2024.08.003"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Dinan TG, Cryan JF. Brain-gut-microbiota axis and mental health. Psychosom Med 79: 920-926, 2017.","DOI":"10.1097\/PSY.0000000000000519"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. Liu B, Wanders A, Wirdefeldt K, et al. Vagotomy and subsequent risk of inflammatory bowel disease: a nationwide register-based matched cohort study. Aliment Pharmacol Ther 51: 1022-1030, 2020.","DOI":"10.1111\/apt.15715"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95. Chu C, Artis D, Chiu IM. Neuro-immune interactions in the tissues. Immunity 52: 464-474, 2020.","DOI":"10.1016\/j.immuni.2020.02.017"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96. Klose CS, Artis D. Neuronal regulation of innate lymphoid cells. Curr Opin Immunol 56: 94-99, 2019.","DOI":"10.1016\/j.coi.2018.11.002"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97. Kabata H, Artis D. Neuro-immune crosstalk and allergic inflammation. J Clin Invest 129: 1475-1482, 2019.","DOI":"10.1172\/JCI124609"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98. Mikami Y, Tsunoda J, Kiyohara H, Taniki N, Teratani T, Kanai T. Vagus nerve-mediated intestinal immune regulation: therapeutic implications of inflammatory bowel diseases. Int Immunol 34: 97-106, 2022.","DOI":"10.1093\/intimm\/dxab039"},{"key":"99","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1136\/gutjnl-2018-317182","volume":"68","author":"AD Frolkis","year":"2019","unstructured":"99. Frolkis AD, Vallerand IA, Shaheen AA, et al. Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression. Gut 68: 1606-1612, 2019.","journal-title":"Gut","ISSN":"https:\/\/id.crossref.org\/issn\/0017-5749","issn-type":"print"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100. Barberio B, Zamani M, Black CJ, Savarino EV, Ford AC. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 6: 359-370, 2021.","DOI":"10.1016\/S2468-1253(21)00014-5"},{"key":"101","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s12888-020-02654-5","volume":"20","author":"A Chinna Meyyappan","year":"2020","unstructured":"101. Chinna Meyyappan A, Forth E, Wallace CJK, Milev R. Effect of fecal microbiota transplant on symptoms of psychiatric disorders: a systematic review. BMC Psychiatry 20: 299, 2020.","journal-title":"BMC Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/1471-244X","issn-type":"print"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102. Simpson CA, Diaz-Arteche C, Eliby D, Schwartz OS, Simmons JG, Cowan CSM. The gut microbiota in anxiety and depression - a systematic review. Clin Psychol Rev 83: 101943, 2021.","DOI":"10.1016\/j.cpr.2020.101943"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103. Stilling RM, van de Wou M, Clarke G, Stanton C, Dinan TG, Cryan JF. The neuropharmacology of butyrate: the bread and butter of the microbiota-gut-brain axis? Neurochem Int 99: 110-132, 2016.","DOI":"10.1016\/j.neuint.2016.06.011"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104. Bourassa MW, Alim I, Bultman SJ, Ratan RR. Butyrate, neuroepigenetics and the gut microbiome: can a high fiber diet improve brain health? Neurosci Lett 625: 56-63, 2016.","DOI":"10.1016\/j.neulet.2016.02.009"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105. Mayer EA, Knight R, Mazmanian SK, Cryan JF, Tillisch K. Gut microbes and the brain: paradigm shift in neuroscience. J Neurosci 34: 15490-15496, 2014.","DOI":"10.1523\/JNEUROSCI.3299-14.2014"},{"key":"106","doi-asserted-by":"publisher","unstructured":"106. Kashiwagi I, Morita R, Schichita T, et al. Smad2 and Smad3 inversely regulate TGF-\u03b2 autoinduction in <i>Clostridium butyricum<\/i>-activated dendritic cells. Immunity 43: 65-79, 2015.","DOI":"10.1016\/j.immuni.2015.06.010"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107. Hayashi A, Sato T, Kamada N, et al. A single strain of <i>Clostridium butyricum<\/i> induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. Cell Host Microbe 13: 711-722, 2013.","DOI":"10.1016\/j.chom.2013.05.013"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108. Kanai T, Mikami Y, Hayashi A. A breakthrough in probiotics: <i>Clostridium butyricum<\/i> regulates gut homeostasis and anti-inflammatory response in inflammatory bowel disease. J Gastroenterol 50: 928-939, 2015.","DOI":"10.1007\/s00535-015-1084-x"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109. Miyaoka T, Kanayama M, Wake R, et al. <i>Clostridium butyricum<\/i> MIYAIRI 588 as adjunctive therapy for treatment-resistant major depressive disorder: a prospective open-label trial. Clin Neuropharmacol 41: 151-155, 2018.","DOI":"10.1097\/WNF.0000000000000299"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110. Dizman N, Meza L, Bergerot P, et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med 28: 704-712, 2022.","DOI":"10.1038\/s41591-022-01694-6"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111. Ebrahimi H, Dizman N, Meza L, et al. Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med 30: 2576-2585, 2024.","DOI":"10.1038\/s41591-024-03086-4"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112. Gareau MG, Wine E, Rodrigues DM, et al. Bacterial infection causes stress-induced memory dysfunction in mice. Gut 60: 307-317, 2011.","DOI":"10.1136\/gut.2009.202515"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113. Jiang C, Li G, Huang P, Liu Z, Zhao B. The gut microbiota and Alzheimer&apos;s disease. J Alzheimers Dis 58: 1-15, 2017.","DOI":"10.3233\/JAD-161141"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114. Narengaowa, Kong W, Lan F, Awan UF, Qing H, Ni J. The oral-gut-brain AXIS: the influence of microbes in Alzheimer&apos;s disease. Front Cell Neurosci 15: 633735, 2021.","DOI":"10.3389\/fncel.2021.633735"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115. Vogt NM, Kerby RL, Dill-McFarland KA, et al. Gut microbiome alterations in Alzheimer&apos;s disease. Sci Rep 7: 13537, 2017.","DOI":"10.1038\/s41598-017-13601-y"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116. Ferreiro AL, Choi J, Ryou J, et al. Gut microbiome composition may be an indicator of preclinical Alzheimer&apos;s disease. Sci Transl Med 15: eabo2984, 2023.","DOI":"10.1126\/scitranslmed.abo2984"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117. Grabrucker S, Marizzoni M, Silajd\u017ei\u0107 E, et al. Microbiota from Alzheimer&apos;s patients induce deficits in cognition and hippocampal neurogenesis. Brain 146: 4916-4934, 2023.","DOI":"10.1093\/brain\/awad303"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118. Kazmi SA, Hsiao EY. Extending genetic risk for Alzheimer&apos;s disease from host to holobiont. Cell 186: 690-692, 2023.","DOI":"10.1016\/j.cell.2023.01.004"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119. Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem 71: 635-700, 2002.","DOI":"10.1146\/annurev.biochem.71.110601.135414"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120. Romero D, Aguilar C, Losick R, Kolter R. Amyloid fibers provide structural integrity to <i>Bacillus subtilis<\/i> biofilms. Proc Natl Acad Sci U S A 107: 2230-2234, 2010.","DOI":"10.1073\/pnas.0910560107"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121. Liang S, Wang T, Hu X, et al. Administration of <i>Lactobacillus helveticus<\/i> NS8 improves behavioral, cognitive, and biochemical aberrations caused by chronic restraint stress. Neuroscience 310: 561-577, 2015.","DOI":"10.1016\/j.neuroscience.2015.09.033"},{"key":"122","doi-asserted-by":"publisher","unstructured":"122. Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson&apos;s disease. Cell 167: 1469-1480.e12, 2016.","DOI":"10.1016\/j.cell.2016.11.018"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123. Streit WJ, Xue QS, Tischer J, Bechmann I. Microglial pathology. Acta Neuropathol Commun 2: 142, 2014.","DOI":"10.1186\/PREACCEPT-1035265697142235"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124. Cersosimo MG, Benarroch EE. Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord 23: 1065-1075, 2008.","DOI":"10.1002\/mds.22051"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125. Hirayama M, Ohno K. Parkinson&apos;s Disease and Gut Microbiota. Ann Nutr Metab 77: 28-35, 2021.","DOI":"10.1159\/000518147"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126. Svensson E, Horv\u00e1th-Puh\u00f3 E, Thomsen RW, et al. Vagotomy and subsequent risk of Parkinson&apos;s disease. Ann Neurol 78: 522-529, 2015.","DOI":"10.1002\/ana.24448"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127. Maini Rekdal V, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science 364: 2019.","DOI":"10.1126\/science.aau6323"},{"key":"128","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1186\/s12888-023-05329-z","volume":"23","author":"L Shi","year":"2023","unstructured":"128. Shi L, Ju P, Meng X, et al. Intricate role of intestinal microbe and metabolite in schizophrenia. BMC Psychiatry 23: 856, 2023.","journal-title":"BMC Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/1471-244X","issn-type":"print"},{"key":"129","doi-asserted-by":"crossref","unstructured":"129. Kraeuter AK, Phillips R, Sarnyai Z. The gut microbiome in psychosis from mice to men: a systematic review of preclinical and clinical studies. Front Psychiatry 11: 799, 2020.","DOI":"10.3389\/fpsyt.2020.00799"},{"key":"130","doi-asserted-by":"crossref","unstructured":"130. Zhu F, Ju Y, Wang W, et al. Metagenome-wide association of gut microbiome features for schizophrenia. Nat Commun 11: 1612, 2020.","DOI":"10.1038\/s41467-020-15457-9"},{"key":"131","doi-asserted-by":"publisher","unstructured":"131. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 130: 1480-1491, 2006.","DOI":"10.1053\/j.gastro.2005.11.061"},{"key":"132","doi-asserted-by":"publisher","unstructured":"132. Pittayanon R, Lau JT, Yuan Y, et al. Gut microbiota in patients with irritable bowel syndrome - a systematic review. Gastroenterology 157: 97-108, 2019.","DOI":"10.1053\/j.gastro.2019.03.049"},{"key":"133","doi-asserted-by":"crossref","unstructured":"133. Jeffery IB, O&apos;Herlihy E, Shanahan F, O&apos;Toole PW. Microbiome alterations in IBS. Gut 69: 2263-2264, 2020.","DOI":"10.1136\/gutjnl-2020-320919"},{"key":"134","doi-asserted-by":"crossref","unstructured":"134. Xiao L, Liu Q, Luo M, Xiong L. Gut microbiota-derived metabolites in irritable bowel syndrome. Front Cell Infect Microbiol 11: 729346, 2021.","DOI":"10.3389\/fcimb.2021.729346"},{"key":"135","doi-asserted-by":"publisher","unstructured":"135. Mizuno S, Masaoka T, Naganuma M, et al. Bifidobacterium-rich fecal donor may be a positive predictor for successful fecal microbiota transplantation in patients with irritable bowel syndrome. Digestion 96: 29-38, 2017.","DOI":"10.1159\/000471919"},{"key":"136","doi-asserted-by":"crossref","unstructured":"136. Kurokawa S, Kishimoto T, Mizuno S, et al. The effect of fecal microbiota transplantation on psychiatric symptoms among patients with irritable bowel syndrome, functional diarrhea and functional constipation: an open-label observational study. J Affect Disord 235: 506-512, 2018.","DOI":"10.1016\/j.jad.2018.04.038"},{"key":"137","doi-asserted-by":"crossref","unstructured":"137. van Praag H, Shubert T, Zhao C, Gage FH. Exercise enhances learning and hippocampal neurogenesis in aged mice. J Neurosci 25: 8680-8685, 2005.","DOI":"10.1523\/JNEUROSCI.1731-05.2005"},{"key":"138","doi-asserted-by":"publisher","unstructured":"138. Villeda SA, Luo J, Mosher KI, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477: 90-94, 2011.","DOI":"10.1038\/nature10357"},{"key":"139","doi-asserted-by":"crossref","unstructured":"139. Li R, Roy R. Gut Microbiota and its role in anti-aging phenomenon: evidence-based review. Appl Biochem Biotechnol 195: 6809-6823, 2023.","DOI":"10.1007\/s12010-023-04423-y"},{"key":"140","doi-asserted-by":"crossref","unstructured":"140. Liu C, Cheung WH, Li J, et al. Understanding the gut microbiota and sarcopenia: a systematic review. J Cachexia Sarcopenia Muscle 12: 1393-1407, 2021.","DOI":"10.1002\/jcsm.12784"},{"key":"141","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40168-022-01243-w","volume":"10","author":"A Parker","year":"2022","unstructured":"141. Parker A, Romano S, Ansorge R, et al. Fecal microbiota transfer between young and aged mice reverses hallmarks of the aging gut, eye, and brain. Microbiome 10: 68, 2022.","journal-title":"Microbiome","ISSN":"https:\/\/id.crossref.org\/issn\/2049-2618","issn-type":"print"},{"key":"142","doi-asserted-by":"crossref","first-page":"2295394","DOI":"10.1080\/19490976.2023.2295394","volume":"16","author":"F Huang","year":"2024","unstructured":"142. Huang F, Cao Y, Liang J, et al. The influence of the gut microbiome on ovarian aging. Gut Microbes 16: 2295394, 2024.","journal-title":"Gut Microbes","ISSN":"https:\/\/id.crossref.org\/issn\/1949-0976","issn-type":"print"},{"key":"143","doi-asserted-by":"crossref","unstructured":"143. Wang L, Chen Y, Wei J, et al. Administration of nicotinamide mononucleotide improves oocyte quality of obese mice. Cell Prolif 55: e13303, 2022.","DOI":"10.1111\/cpr.13303"},{"key":"144","doi-asserted-by":"crossref","unstructured":"144. Messaoudi M, Lalonde R, Violle N, et al. Assessment of psychotropic-like properties of a probiotic formulation (<i>Lactobacillus helveticus<\/i> R0052 and <i>Bifidobacterium longum<\/i> R0175) in rats and human subjects. Br J Nutr 105: 755-764, 2011.","DOI":"10.1017\/S0007114510004319"},{"key":"145","doi-asserted-by":"crossref","unstructured":"145. Schmidt K, Cowen PJ, Harmer CJ, Tzortzis G, Errington S, Burnet PW. Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers. Psychopharmacology (Berl) 232: 1793-1801, 2015.","DOI":"10.1007\/s00213-014-3810-0"},{"key":"146","doi-asserted-by":"crossref","unstructured":"146. Jacka FN, O&apos;Neil A, Opie R, et al. A randomised controlled trial of dietary improvement for adults with major depression (the &apos;SMILES&apos; trial). BMC Med 15: 23, 2017.","DOI":"10.1186\/s12916-017-0791-y"},{"key":"147","doi-asserted-by":"crossref","unstructured":"147. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent <i>Clostridium difficile<\/i>. N Engl J Med 368: 407-415, 2013.","DOI":"10.1056\/NEJMoa1205037"},{"key":"148","doi-asserted-by":"crossref","unstructured":"148. Gacesa R, Kurilshikov A, Vich Vila A, et al. Environmental factors shaping the gut microbiome in a Dutch population. Nature 604: 732-739, 2022.","DOI":"10.1038\/s41586-022-04567-7"},{"key":"149","doi-asserted-by":"crossref","unstructured":"149. Dsouza M, Menon R, Crossette E, et al. Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers. Cell Host Microbe 30: 583-598.e8, 2022.","DOI":"10.1016\/j.chom.2022.03.016"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/2\/65_5318-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T03:33:32Z","timestamp":1768620812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/2\/65_5318-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":149,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5318-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"article-number":"5318-25"}}